StudyFinder

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Status: Recruiting

The purpose of this study is to understand if a new treatment (pasritamig) added to best supportive care (including radiation, steroids, pain medication, or medications to strengthen your bones) for metastatic castration-resistant prostate cancer will work better than the best supportive care alone.

I'm interested

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosis of metastatic castration-resistant prostate cancer (mCRPC): Disease is metastatic either to bone, any lymph node, or both without clear evidence of metastasis to visceral organs
• PSA greater than or equal to (>=) 2 nanogram per milliliter (ng/mL)
• at least able to walk and so all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:

• blood clot in the last month
• active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications
• significant lung disease
• another cancer
• heart disease in the past six months
• see link to clinicaltrials.gov for complete Exclusion criteria
Interventions:

Drug: Best Supportive Care (BSC), Biological: Pasritamig, Other: Placebo

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), mCRPC, metastatic castration-resistant prostate cancer

Study Contact: Felicia Lin - lin00808@umn.edu
Principal Investigator: Nicholas Zorko
Phase: PHASE3
IRB Number: STUDY00026133
See this study on ClinicalTrials.gov

Back